Company intelligence / Profile preview
Qrons
New York, New York, United States
- Ownership
- Private
- Employees
- ~12
- Development stage
- Other
01
Overview
Qrons has developed two main pre-clinical programs: QS100 (an injury-specific, 3D printable MSC–synthetic hydrogel implant for penetrating brain injuries) and QS200 (an injectable MSC–synthetic hydrogel for diffuse/concussion injuries). Both are at pre-clinical stage and have not yet reported human clinical data.
- Therapeutic areas
- Infectious DiseasesNeurology
- Modalities
- Mesenchymal stem cell therapyHydrogel-based drug delivery therapyDevice
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Qrons.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qrons.